This CBD stock could potentially generate 716.8% Profit

This CBD stock could potentially generate 716.8% Profit in no time... If you don't know, consumers just celebrated the largest cannabis holiday on April 20th. Now, this holiday may have increased earnings for various cannabis companies, as well as cannabidiol (CBD) companies. However, with CBD - it's different. You see, CBD is non-psychoactive and helps provide pain relief, as well as treat various symptoms. Consequently, CBD is becoming widely accepted by consumers and countries. For example, in the U.S., CBD became legal after the Farm Bill that passed in late 2018. That in mind, consumers could easily find CBD products across the U.S. In turn, we may actually see some CBD companies generating more revenues and earnings than cannabis companies. Now, Bethany Gomez, a researcher for The Brightfield Group estimate that the CBD market will reach $22B by 2022. What's even more positive is Europe is just starting to get into the game and our next pick is a first-mover in the European CBD Market. That said, CBD companies could experience exponential growth rates with such a large market. Not only that, large-cap drug stores like CVS and Walgreens have bet on CBD. Additionally, CVS and Walgreens noted they would offer CBD products in more than 2,000 stores across the U.S. But these companies need to find a reputable source for CBD products. Now, this one little-known company focused on CBD has figured out how to create CBD Isolate for $744 per kg. Their first crop is due in August 2019 and expected to produce 16,000 kg of CBD Isolate. The current U.S. wholesale price for CBD Isolate is $6,077 per kg. That would be a 716.8% Profit Margin! With CVS and Walgreens offering CBD products, it wouldn't be surprising to see either of these two large drug store companies to strike a partnership with this CBD company. Here are four major reasons why this CBD company could break out BIG: Massive 3,706 acre Hemp farm in Poland scheduled to have its first crop in August With a production output estimated at 16,000 kg in 2019, forecasted revenue can be expected to be an impressive $97.23 million and $197 million in 2020. Raised CAD $24.36 in April, 2019 An extraction contract with DragonFly Biosciences, Europe's largest CBD retailer, is worth $48 million over the next three years. It seems like this company's future is unstoppable. Who can compete with them to produce at these levels? We haven't found one yet... It's always fun to share a secret like this with investors like you, but the word may get out quickly and the stock may not sit at these levels for long. Read full Research Report on Microsmallcap Now! This is a PAID ADVERTISEMENT provided to customers of Schaeffer's Investment Research. Although we have sent you this email, Schaeffer's not specifically endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above. Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click here. DISCLAIMER: In accordance with Section 17(b) of the Securities Act of 1933, you are hereby advised that Schaeffer’s Investment Research, Inc. "Schaeffer’s" is receiving a fee of over $1000.00 in cash, from an independent third party as compensation for the distribution of this advertisement. Schaeffer’s has not determined if the statements and opinions of the advertiser are accurate, correct or truthful. The purpose of this advertisement, like any advertising, is to provide publicity for the advertising company, its products or services. You should not rely on the information presented; you should do independent research to form your own opinion and decision. Information contained in our disseminated emails does not constitute investment, legal or tax advice upon which you should rely. The purchase of high-risk securities may result in the loss of your entire investment. Advertisements received by you are not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the States or other jurisdictions in which the security is eligible for sale. Advertisements distributed through disseminated emails are not disclosure documents. If you are considering purchasing any securities of an advertised company, you should call your State Securities Administrator to determine if the security may be sold in your State. Many companies have information filed with State securities regulators who may be able to supply you with additional information. You also should read and review, if and to the extent available, any information concerning an advertised company available at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at http://‌www.‌sec.‌gov and the Financial Industry Regulatory Authority (the "FINRA") at http://‌www.‌FINRA.‌org. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud at http://‌www.‌sec.‌gov/‌consumer/‌cyberfr.‌htm, as well as related information published by the NASD on how to invest carefully. You are responsible for verifying all claims and conducting your own due diligence. You agree and acknowledge that any hyperlinks to the website of (1) an advertised company, (2) the party issuing or preparing the information for the advertised company, or (3) other information contained in our disseminated emails is provided only for your reference and convenience. We are not responsible for the accuracy or reliability of these external sites, nor are we responsible for the content, advertising, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated email or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on us, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. You also acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser. You acknowledge that you will consult with your own advisers regarding any decisions as to any advertised company. Schaeffer's Investment Research 5151 Pfeiffer Road, Suite 250 Cincinnati, Ohio 45242